MAR 28, 2019 10:30 AM PDT

Medical Cannabis Pharmacogenomics and Drug Interactions

C.E. Credits: P.A.C.E. CE Florida CE
  • Chief Science Officer, International Research Center on Cannabis and Health
      Dr. Jahan Marcu has over 15 years of experience in cannabinoid research, policy, and operations. He has been a passionate advocate focused on consumer safety and the medical benefits of cannabis. He is also among a select group of professionals globally that has earned a PhD focused on the endocannabinoid system (with research on the structure and function of cannabinoid receptors, molecular pharmacology of the endocannabinoid system, and the role of the ECS in bone).

      He is presently the Editor-In-Chief of the American Journal of Endocannabinoid Medicine. He is the Chief Science Officer and co-founder of the International Research Center on Cannabis and Health, a community-based institute that collaborates with universities, researchers, foundations, state institutions, and others to leverage the highest caliber talent in the field. He is also founder and past-chair of the Cannabis Chemistry Sub-division of the American Chemical Society, the world's largest and oldest professional scientific society. Further illustrating the recognition earned through his efforts, he has been asked to serve on multiple expert government advisory and trade association committees, as well as scientific organizations including ASTM (D37 Subcommittee chair), AHPA Cannabis committee (past-chair), ACS Cannabis Chemistry Subdivision (CANN), AOCS, AOAC, IACM(past BOD), and IMCPC (co-founder).


    The therapeutic applications of medical cannabis and cannabinoid drugs is controversial, however the number of medical conditions in which cannabinoids and cannabis have shown promise as therapeutic treatments is expanding. The occurrence of side effects from cannabinoids is still a concern, especially with the wide variability in drug levels and response that has been observed. This is compounded by possible interactions with prescription drugs. Application of pharmacogenomics (PGx) and knowledge of drug-drug interactions could help patients and doctors navigate the complexities of combining prescription drugs and cannabis compounds. Genetic variants in several drug metabolizing enzymes may impact response to cannabinoids, including CYP3A4, CYP2C9, and CYP2C19. Furthermore, drug interactions caused by cannabinoids may also be mediated by drug metabolizing enzymes (e.g. CYP2C9, CYP2D6, CYP2B6, CYP1A1) and possibly drug transporters such as ABCB1. Understanding how commonly prescribed drugs and cannabinoids interact could help reduce risks associated with polydrug regimens. This presentation will discuss PGx testing for cannabis and potential impacts on commonly prescribed pharmaceuticals.


    Learning Objectives: 

    1. Be able to discuss CYPs involved with cannabinoid metabolism 
    2. Know potential risks associated with oral CBD administration

    Show Resources
    Show Resources
    • See more